Ronald Andrews

Ronald Asbury Andrews was the founder of Bethesda Group Fund, founded in 2015, serving as Principal.
Current jobs include Executive Chairman at Dxcover Ltd. since 2023; Director at Oxford Immunotec Ltd. since 2015; Director at Mission Hospital Foundation; Director at Quest Diagnostics TB LLC since 2015; Independent Director at Cellmax, Inc. since 2023; Independent Director at Precipio, Inc. since 2021; Independent Director at Plus Therapeutics, Inc. starting 2026; Director at Precipio Diagnostics LLC; Trustee at Wofford College; and Member-Supervisory Board at Agendia, Inc. since 2023.
Former jobs include Chief Executive Officer-GE Molecular Diagnostics at Clarient, Inc. from 2010 to 2012; Chief Executive Officer-Clarient Business Unit at GE Healthcare, Inc. in 2012; Chief Executive Officer & Director at Insight Molecular Diagnostics, Inc. in 2022; Chief Executive Officer & Director at Twinstrand Biosciences, Inc. from 2023 to 2024; Executive Chairman at SimBioSys, Inc. from 2022 to 2024; Independent Non-Executive Director at Oxford Immunotec Global Ltd. from 2015 to 2021; Director at Cardiac Science Corp.
from 2009 to 2010; Independent Director at Orion Health Group Ltd. and Orion Health Ltd. from 2016 to 2018; Director at Insight Genetics, Inc. from 2015 to 2019; Vice President at Immucor, Inc.; Vice President-Marketing at Roche Diagnostics Corp.; President-Genetic Sciences Division at Thermo Fisher Scientific, Inc. from 2013 to 2014; Senior Vice President-Global Marketing at Roche Molecular Systems, Inc. from 2000 to 2004; Senior Marketing Manager-Business Unit Operations at Abbott Diagnostics, Inc.; President-Medical Sciences at Life Technologies Corp.
from 2012 to 2013; Member-Governors Board at CancerLinQ LLC from 2016 to 2023; and Managing Partner at Ph Blueprint.
Education includes an undergraduate degree from Wofford College, conferred in 1981.